Pharma Digest

Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience playAmbrosia scores $100M series B to take next-gen oral GLP-1 into the clinicMerck enlists antibody hunter Infinimmune for $838M biobucks pact

Mapping the Trillion-Gene Universe: The Startup That Wants to Teach AI the Language of LifeWhy Data Infrastructure Determines AI Success in Drug DiscoveryPhenoTips, Health Institutions Launch C$5.4M AI Genomic Medicine Initiative in Canada

AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flopsLilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75BMerck dives into detailed phase 3 data showing PCSK9 pill easily outswims rivals

The Value of Prediction, and Cost of Success, in Drug HuntingMerck hands over $20M in IBD drug target deal with Flagship's QuotientThe N-of-1 Revolution in Personalized Medicine

- Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition- OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline- Sarepta's big bet on Arrowhead's siRNA assets yields early data

Baylor College of Medicine Taps Nautilus’ Voyager for Cancer ProteomicsThe Download: OpenAI is building a fully automated researcher, and a psychedelic trial blind spotFrom scientist to bioinformatician: how AI coding tools dissolved the activation energy barrier

Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trialSTAT+: A biotech turns to Apple Watch to study its Parkinson’s drugWhich FDA Division Has the Most Stability As AI Tools Get Adopted Across the Agency?

With its first AI mod­el re­lease, Xaira tests scal­ing laws in vir­tu­al cellsNVIDIA GTC 2026: Agentic AI Inflection Hits Healthcare and Life SciencesDOE Announces $293M Funding Opportunity as Genesis Mission Moves Toward Operational Phase

Pfizer's hotly tipped breast cancer prospect delivers phase 2 winAspen's 1-year data for Parkinson's cell therapy plant seeds for phase 3 trialCrossbow hits $77M series B round to bankroll quiver of T-Bolts

Roche inks Nvidia deal to bolster AI factory, speed drug and diagnostic developmentWhy most labs are not ready for AI: Cenevo shares what must changeFrench AI Startup Building World Models Raises $1.03 billion

Structure touts 16% weight loss for aleniglipron as 'highest efficacy' for an oral GLP-1 yetR1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatmentDanish biotech Gubra plots Roivant-like model to churn out new companies

Stop asking for an AI strategy: 3 questions clinical leaders should ask insteadThe Real Test for AI Diagnostics Isn’t Performance — It’s Clinical AdoptionReal-World Evidence Meets Machine Learning: What It Takes to Future-Proof Evidence Generation

CytomX surges on positive data for ‘masked’ ADC in colorectal cancerAstellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 yearsJAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity — NeuroSense Therapeutics

Startup Waiv Spins Out of Owkin With $33M to Bring AI Precision to Cancer DecisionsArtificial Intelligence and the Data Quality Problem No One Can IgnoreMicrosoft Enters Healthcare Chatbot Race with Copilot Health

GSK’s RSV vaccine wins broader FDA clearanceBimzelx tops Skyrizi in head-to-head psoriatic arthritis trialWith FDA go ahead, a China biotech notches a first in cell therapy testing

An AI Driven Approach to Address the Non-Responder Gap in Radiopharmaceutical TherapyAgentic AI Swarms Degrade Decision-MakingSTAT+: AI agents are rapidly spreading in health care, but validation is lacking

Ultragenyx gene therapy hits co-primary endpoint in phase 3 rare disease study, teeing up potential winBridgeBio's muscle weakness data impress ahead of FDA filingFledgling French biotech pens $128M deal for Kezar's preclinical protein degrader program

STAT+: New nonprofit launches with at least $500 million to modernize scientific process for AI eraBota/Enhe’s SAION AI push toward closed‑loop, machine‑protocol‑driven biomanufacturingTailored Training Can Address Biopharma Skills Shortage

Regeneron's obesity drug shows Zepbound-like efficacy in phase 3Tenacia builds $308M biobucks deal with Rapport to develop epilepsy drug in greater China$270M RNA Drug Spinout Targets Rare Genetic Cardiomyopathies

Smarter Filings, Smarter FactoriesHealth AI startup to benefit from $1 billion funding round for Yann LeCun’s AMIBreakout Ventures launches $114M AI-focused fund

Vertex races to FDA after phase 3 kidney disease data impress analystsServier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One BiopharmaFDA reconsidering Capricor’s snubbed DMD cell therapy after 'lifting' rejection

CVS, Humana & More Are Turning to Google’s AI ModelsAI Startups Are Tying Fees to Completed Tasks. Will Hospitals Buy In?For Anthropic, Pragmatism Is the More Trustworthy Position

FDA issues speedy approval to J&J’s Tecvayli-Darzalex comboXenon phase 3 epilepsy readout 'blows away' expectations, stock soarsBMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3

Future of Health Tech: From Structured Data to Scalable AICapturing the Vibe at ViVE 2026, Healthcare Executives Share Insights on Medication Adherence and Implementing AI Privacy Expectations in Consumer AI Tools: How Patient Use of ChatGPT Health and Claude Differs From HIPAA-Regulated Care

Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing dealFDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, TruqapRoche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'

Opinion: AI could revolutionize antibiotics — but the market is standing in the wayThird Way Health Secures $15M to Streamline Front-Office Operations for Medical PracticesIn­vestors are pump­ing mon­ey in­to AI tools for health in­sur­ers

UCB enters TCE space with $1.1B deal for Chinese biotech's autoimmune candidateNew cancer cases prompt Kyowa to discontinue late‑stage autoimmune disease programFDA details rationale for rejecting rare disease gene therapy from Regenxbio

STAT+: FDA grants breakthrough status to generative AI chatbot AI Startups ROI Reckoning: What 4 VCs Say Matters NowActionable AI in Clinical Settings: Trust and Transparency as the Core Operating System

[AI Generated Biotech and Pharma News]Ascendis wins FDA approval of dwarfism drugLynk points to phase 3 eczema win as more proof of next-gen JAK inhibitor's potentialNovo Nordisk teams with Langer-founded biotech for oral obesity drugs

Senhwa's CX-4945 targets CK2 kinase with dual tumor and immune modulatory mechanisms; CellType's AI platform aims to expand indications and improve clinical success via multi-omics analysis and translational validation.Generate's $400M IPO signals strong investor confidence, driven by AI-designed pipelines including GB-0895, an AI-optimized TSLP inhibitor with potential to disrupt asthma treatment.hysiology remains foundational for translating AI and sensor data into clinically relevant therapies, aiding in anticipating off-target effects and enhancing regulatory acceptance.

BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rivalUniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapyAtrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates

[AI Generated AI in Pharma News]Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycleEarendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCsXtalPi's AI + Robotics Platform Powers First Clinical Milestone for ReviR's Rare Neurological Drug RTX-117

[AI Generated Pharma and Biotech News]United Therapeutics' phase 3 win tees up filing to challenge J&J in cardiac conditionFDA fully releases clinical hold on Intellia CRISPR gene therapyEarendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs

[AI Generated AI in Pharma and Biotech News]QScreen AI secured CAD 500,000 in financing to expand its AI and quantum-driven health screening solutions across North America and Mexico.Investment is surging in the health insurance sector, highlighted by Handl Health’s $14.2 million Series A funding for AI tools that streamline underwriting and claims management.Roche and Insilico Medicine (in collaboration with Pfizer) are leading a shift toward AI-driven drug discovery, using deep learning and generative AI to identify therapeutic candidates and optimize protein engineering.

[AI Generated Pharma News] Earendil Labs and WuXi XDC have partnered to integrate machine learning with the WuXiTecan-2 platform to optimize the design and targeting precision of antibody-drug conjugates (ADCs).ImmVira is expanding clinical trials for MVR-T3011, a genetically engineered oncolytic virus, to treat BCG-naïve bladder cancer patients as a dual-action alternative to traditional therapies.Protagonist Therapeutics exited its profit-sharing deal with Takeda for the drug rusfertide, accepting a $400 million one-time payment to independently fund its broader pipeline, including the asset ICOTYDE™.

[AI Generated Pharma News]Pfizer has acquired the Chinese commercialization rights for Sciwind’s GLP-1 drug, ecnoglutide, in a deal valued at up to $495 million to target the region's growing metabolic disorder market.GSK is expanding its respiratory and cardiovascular pipeline through a $950 million acquisition of 35Pharma, gaining access to a promising activin signaling inhibitor for pulmonary hypertension.Novo Nordisk has entered a potential $2.1 billion partnership with Vivtex to leverage proprietary technology for developing oral formulations of biologic drugs like GLP-1 therapies.

[AI Generated AI in Drug Discovery News]Dimension has secured $500 million to fund approximately 24 companies, aiming to integrate computational power with life sciences to accelerate drug discovery.The BiopharmaTrend 2026 watchlist identifies startups founded in 2021 that are using AI platforms to move away from single-asset strategies toward more precise, platform-based drug development.Y Combinator is backing the Yale spinout Patientdesk.ai, which utilizes "Agentic AI" to eliminate inefficiencies and improve data-driven forecasting within clinical trials.

[AI Generated AI in Drug Discovery News]Turbine is utilizing a recently secured $25 million in Series B funding to advance its "lab-in-the-loop" AI platform that simulates biological processes to reduce the cost and risk of drug discovery.Evinova has established strategic partnerships with AstraZeneca, Astellas, and Bristol Myers Squibb to integrate AI across the drug development spectrum, focusing on clinical trial data analysis and early-stage candidate selection.Owkin has launched K Pro, an AI co-pilot that uses federated learning and biological reasoning to analyze fragmented biomedical data, aiming to significantly accelerate drug discovery timelines and enhance precision medicine.

[AI generated Pharma News]Turbine's Virtual Lab: The Hungary-based firm raised $25 million to scale its AI platform that simulates cellular biology to accelerate drug discovery.Global Licensing Surges: Highlighting Chinese expansion, Frontier signed a $1 billion kidney disease deal with GSK, while Harbour BioMed penned a $1.2 billion cancer treatment agreement with Solstice. Astellas & Vir Partnership: A $1.7 billion collaboration focuses on VIR-5500, a prostate cancer therapy that demonstrated a 45% response rate in early trials.